Martha Gulati: Oral MHT Is Associated With Increased Thrombotic Risk
Martha Gulati, Director of the Davis Women Heart Center at Houston Methodist DeBakey Heart and Vascular Center, shared The BMJ‘s post on X:
“Consistent with prior research, oral MHT is associated with increased thrombotic risk.
The same is not seen with transdermal MHT.”
The BMJ (British Medical Journal) shared a post on X about a recent article by Julie Berggreen et al., adding:
“Compared with no use of hormone therapy, oral menopausal hormone therapy was associated with increased venous thromboembolic risk regardless of dosage and treatment duration, finds study.
No increased thrombotic risks were observed with transdermal therapy.”
Title: Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study
Authors: Julie Berggreen, Nelsan Pourhadi, Hannah Wood-Kurland, Ellen Løkkegaard, Christian Torp-Pedersen, Amani Meaidi

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?